#Washington D.C. #AusperBio #AHB-137 #Hepatitis B

AusperBio Unveils Late-Breaking Data at AASLD 2025

On November 8, 2025, AusperBio Therapeutics presented compelling findings from two Phase II studies at the American Association for the Study of Liver Diseases (AASLD) annual meeting. These studies focused on AHB-137, an innovative therapy geared towards patients with chronic hepatitis B (CHB) who are HBeAg-negative.

Study Overview

The pooled results showcased the sustained antiviral responses achieved at the 48-week mark following treatment with AHB-137. Specifically, the presentation highlighted the treatment's efficacy in CHB patients who are already receiving nucleos(t)ide analog (NA) therapy. The data originated from two multicenter, randomized Phase II studies, identified as Phase IIa (NCT06115993) and Phase IIb (NCT06550128).
These studies are crucial as they provide insights into the treatment’s long-term effectiveness and safety.

Key Findings

The outcomes demonstrated that AHB-137 facilitates strong and sustained antiviral responses, with complete responses (HBsAg < 0.05 IU/mL and HBV DNA below the lower limit of quantification) observed in several participants. Notably, the 300 mg, 24-week regimen achieved the most impressive response rates, demonstrating a consistency across various baseline HBsAg strata.

Moreover, the data indicated that AHB-137 was generally well tolerated, with no new safety signals emerging during the off-treatment period. This positive safety profile strongly supports further development of AHB-137 as a potential functional cure for chronic hepatitis B infection.

Details of the Presentation

• - Publication Number: 5022
• - Date and Time: November 8, 2025, 8:00 am – 5:00 pm ET
• - Abstract Title: High Proportion of Participants Achieved Sustained Complete Response 24 Weeks After End of AHB-137 Treatment in HBeAg Negative Chronic Hepatitis B Participants on NA Therapy Pooled Analysis of Two Phase 2 Studies in China
• - Session: Saturday Late Breaking Posters (